The inhibitory effects of alphaxalone on M1 and M3 muscarinic receptors expressed in Xenopus oocytes
- PMID: 12873933
- DOI: 10.1213/01.ANE.0000068985.78588.E1
The inhibitory effects of alphaxalone on M1 and M3 muscarinic receptors expressed in Xenopus oocytes
Abstract
Alphaxalone is a neurosteroid anesthetic, but its mechanisms of action are not completely understood. Muscarinic receptors are involved in a variety of neuronal functions in the brain and autonomic nervous system, and much attention has been paid to them as targets of anesthetics. In this study, we investigated the effects of alphaxalone on M(1) and M(3) muscarinic receptors using the Xenopus oocyte expression system. Alphaxalone inhibited acetylcholine-induced currents in oocytes expressing M(1) receptors at clinically relevant concentrations. Alphaxalone also suppressed acetylcholine-induced currents in oocytes expressing M(3) receptors. The half-maximal inhibitory concentration values for the inhibition of M(1)- and M(3)-mediated currents were 1.8 +/- 0.6 micro M and 5.3 +/- 1.0 micro M, respectively. GF109203X, a selective protein kinase C inhibitor, had little effect on the inhibition of acetylcholine-induced currents by alphaxalone in oocytes expressing these receptors. Alphaxalone inhibited the specific binding of [(3)H]quinuclidinyl benzilate to oocytes expressing M(1) or M(3) receptors. These findings suggest that alphaxalone at clinically relevant concentrations inhibits the function of M(1) and M(3) receptors through a protein kinase C-independent mechanism by interfering with the [(3)H]quinuclidinyl benzilate binding sites on the receptors.
Implications: Alphaxalone, a neurosteroid anesthetic, inhibited the function of muscarinic M(1) and M(3) receptors and the specific binding of [(3)H]quinuclidinyl benzilate ([(3)H]QNB) to oocytes expressing these receptors. These findings suggest that alphaxalone inhibits these receptors by interfering with the QNB binding sites.
References
-
- Compagnone NA, Mellon SH. Neurosteroids: biosynthesis and function of these novel neuromodulators. Front Neuroendocrinol 2000; 21: 1–56.
-
- Holzbauer M. Physiological aspects of steroids with anaesthetic properties. Med Biol 1976; 54: 227–42.
-
- Child KJ, Currie JP, Dis B, et al. The pharmacological properties in animals of CT1341: a new steroid anaesthetic agent. Br J Anaesth 1971; 43: 2–13.
-
- Harrison NL, Simmonds MA. Modulation of the GABA receptor complex by a steroid anaesthetic. Brain Res 1984; 323: 287–92.
-
- Cottrell GA, Lambert JJ, Peters JA. Modulation of GABAA receptor activity by alphaxalone. Br J Pharmacol 1987; 90: 491–500.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
